Pdt Partners, LLC Bio Atla, Inc. Transaction History

Pdt Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $227,456 - $918,334	-77,366 Reduced 75.95%	24,496 $189,000
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $13,715 - $34,641	6,439 Added 6.75%	101,862 $290,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $417,952 - $1.79 Million	95,423 New	95,423 $477,000
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $142,120 - $231,506	-7,480 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $220,211 - $327,175	7,480 New	7,480 $220,000

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $63.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.